Abstract: Embodiments of the present disclosure pertain to compositions that include a liquid formulation comprising a molecule selected from the group consisting of riluzole, a derivative of riluzole, an analog of riluzole, a pharmaceutical equivalent of riluzole, a benzothiazole-based molecule, combinations thereof, and salts thereof. The liquid formulations may also include a solubilizing agent. Additional embodiments of the present disclosure pertain to methods of treating a condition or disease in a subject by administering to the subject a composition of the present disclosure. The condition or disease to be treated may include spinal cord injury, and the administration may occur by parenteral administration. In some embodiments, the administered molecule may have an absorption half-life of less than 1.5 hours, an elimination half-life of more than 10 hours, and a bioavailability of more than 65%. Additional embodiments of the present disclosure pertain to methods of making the compositions.